Hypoestrogenic atrophy of vulvovaginal and lower urinary tract tissues.
Also known as: atrophic vaginitis, vulvovaginal atrophy, GSM, genitourinary syndrome of menopause
Overview
A constellation of vulvar, vaginal, and lower urinary tract signs and symptoms due to decreased estrogen, now termed Genitourinary Syndrome of Menopause (GSM) by NAMS/ISSWSH (2014). Includes dryness, burning, dyspareunia, urinary urgency, dysuria, and recurrent UTIs.
Epidemiology
Affects 27-84% of postmenopausal women; underdiagnosed because patients and clinicians often do not raise the topic. Also occurs with surgical menopause, postpartum lactation, antiestrogen therapy (aromatase inhibitors, GnRH agonists, tamoxifen variably).
Try two board-style Atrophic Vaginitis questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1ReproductiveMedium
A 45-year-old female has not had a period in 14 months. She has hot flashes, night sweats, vaginal dryness, dyspareunia, and urinary urgency. FSH is 68 IU/L. She is interested in treatment but concerned about breast cancer risk. She has no personal or family history of breast cancer. Her last mammogram was normal. Which of the following is the most appropriate therapy for her genitourinary symptoms?
ADaily oral raloxifene
BSystemic oral estrogen
CLow-dose vaginal estrogen
DTestosterone cream
ESelective serotonin reuptake inhibitor
Reveal answer & full explanation
Correct answer: C — Low-dose vaginal estrogen
ADaily oral raloxifene
BSystemic oral estrogen
CLow-dose vaginal estrogen✓
DTestosterone cream
ESelective serotonin reuptake inhibitor
Why Low-dose vaginal estrogen is correct
Genitourinary syndrome of menopause (GSM) encompasses vulvovaginal atrophy plus urinary symptoms from estrogen deficiency; it affects 50-80% of postmenopausal women.
Low-dose vaginal estrogen (cream, ring Estring, tablet/suppository Vagifem) has minimal systemic absorption, causes no endometrial stimulation at low doses, requires no progestogen, and per American College of Obstetricians and Gynecologists (ACOG) and North American Menopause Society (NAMS) guidance may be considered even in breast cancer survivors whose symptoms persist despite nonhormonal therapy, after shared decision-making with their oncologist.
It is the preferred therapy when the treatment target is vaginal dryness, dyspareunia, and urinary urgency, particularly in a woman worried about breast exposure.
Why the others are wrong
Selective serotonin reuptake inhibitor — SSRIs address vasomotor symptoms (hot flashes) but do not treat genitourinary symptoms such as vaginal dryness and dyspareunia (confused-with vasomotor therapy).
Testosterone cream — testosterone is not FDA approved for genitourinary syndrome of menopause and is not a first-line therapy for vulvovaginal atrophy (right-concept-wrong-hormone).
Systemic oral estrogen — systemic therapy exposes the breast and endometrium far more than local therapy and is not required to relieve genitourinary symptoms, which respond to low-dose vaginal estrogen even in women already taking systemic hormone therapy (overtreatment for a local target).
Daily oral raloxifene — a selective estrogen receptor modulator (SERM) that appeals to a woman worried about breast cancer because it lowers invasive breast cancer risk, but it has no estrogenic effect on the vaginal epithelium, so it does not relieve dryness or dyspareunia and can worsen hot flashes (confused-with ospemifene).
Additional high-yield points
Ospemifene (Osphena): oral selective estrogen receptor modulator (SERM), effective for dyspareunia, may cause hot flashes, contraindicated in breast cancer.
Prasterone (dehydroepiandrosterone (DHEA) vaginal suppository, Intrarosa): local DHEA converted to estrogen and androgen in vaginal tissue.
Non-hormonal lubricants: appropriate for mild symptoms or women who cannot use any estrogen.
Question 2ReproductiveMedium
A woman has dyspareunia and vaginal dryness several years after menopause. Which of the following best explains these symptoms?
Why Estrogen deficiency causing urogenital atrophy is correct
Genitourinary syndrome of menopause results from estrogen loss thinning the vaginal and urethral epithelium.
Atrophy produces dryness, loss of elasticity, dyspareunia, and recurrent urinary symptoms.
Vaginal moisturizers, lubricants, or low-dose local estrogen reverse the changes.
Why the others are wrong
Progesterone excess thickening the endometrium — Progesterone does not thin vaginal tissue, and the postmenopausal state is hypoestrogenic, not progesterone-driven (hormone-mismatch trap).
Pelvic floor muscle hypertonicity causing entry pain — Hypertonic pelvic floor muscles can produce introital dyspareunia, but they do not thin the epithelium or explain the vaginal dryness paired with it here (pain-mechanism trap).
Lichen sclerosus of the vulvar skin — Lichen sclerosus causes itchy white parchment-like vulvar plaques rather than diffuse atrophic dryness, and is not estrogen-dependent (vulvar-mimic trap).
Candida vulvovaginitis causing mucosal irritation — yeast infection can make intercourse painful, but candidiasis depends on estrogen-supported vaginal glycogen and is less common after menopause without hormone therapy, and it typically causes itching and thick white discharge rather than dryness (infection-mimic trap).
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Atrophic Vaginitis (Genitourinary Syndrome of Menopause) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Lack of vaginal intercourse (loss of vascular response)
Pathophysiology
Estrogen deficiency leads to thinning of the vaginal epithelium with loss of glycogen-rich superficial cells, increase in vaginal pH (>5), decrease in lactobacilli, reduced lubrication, decreased elasticity, and shortening of the vagina. Similar atrophic changes affect the urethra and trigone, contributing to lower urinary tract symptoms.
Clinical presentation
Symptoms
Vulvovaginal: dryness, burning, irritation, dyspareunia, postcoital bleeding, loss of lubrication
Lichen sclerosus or lichen planus — Architectural changes (loss of labia minora, agglutination), white plaques, severe pruritus; lichen sclerosus spares the vagina, whereas erosive lichen planus involves it — biopsy
Contact or allergic dermatitis — Recent product exposure; erythema, fissures
Vulvar intraepithelial neoplasia or carcinoma — Persistent plaque, ulcer, or pigmented lesion — biopsy
Recurrent UTI (alternative cause) — Positive urine culture; address pathogen and contributing factors
Diagnostic workup
Diagnostic criteria
Clinical — typical symptoms and exam findings in a hypoestrogenic patient, with exclusion of infection and dermatoses. Biopsy any suspicious lesion.
If insufficient, vaginal estrogen may be considered with oncology input; current evidence does not show increased recurrence with low-dose vaginal estrogen in most settings
Aromatase inhibitors may have additive vaginal effects — patients on these benefit most from vaginal moisturizers, with vaginal DHEA or low-dose estrogen considered on a case-by-case basis
Second-line / adjunct
Systemic menopausal hormone therapy if vasomotor symptoms also present — though local therapy is preferred for isolated GSM
Pelvic floor physical therapy for associated dyspareunia or vaginismus
Energy-based therapies (CO2 laser, radiofrequency) — FDA has cautioned that efficacy and safety are not established; not first-line
Complications
Sexual dysfunction, reduced quality of life
Recurrent UTI
Bleeding from friable atrophic tissue (must rule out endometrial pathology in postmenopausal bleeding)
Vaginal stenosis
PANCE pearls
Postmenopausal bleeding is endometrial cancer until proven otherwise — even when atrophic vaginitis is suspected, evaluation with endometrial sampling and/or transvaginal ultrasound is required.
Low-dose vaginal estrogen has minimal systemic absorption and does not require concurrent progestin; it is safe for long-term use per NAMS.
Vaginal pH >5 with paucity of lactobacilli on wet mount supports the diagnosis.
Symptoms of GSM, unlike vasomotor symptoms, tend to worsen rather than improve with time without treatment.
Vaginal estrogen is acceptable in many breast cancer survivors, but should be a shared decision with their oncologist.
References
NAMS 2020 — NAMS 2020 Genitourinary Syndrome of Menopause Position Statement (Menopause 2020)
ACOG PB 141 — ACOG Practice Bulletin 141: Management of Menopausal Symptoms
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.